Upcoming events and seminars with Dr. Klaus Rose
Regulatory Affairs Professionals Society (RAPS) Regulatory Conference Europe 13-14 May 2019 in Brussels, Belgium. Pediatric session Monday May 13 11.00 – 12.00h AM. https://www.raps.org/europe-2019/home
2nd Kiev Clinical Research Forum 16-17 May 2019 www.conference-pharmasich.com
Pediatric Drug Development Masterclass Monday 27 May 2019, Basel, Switzerland Trainer: Klaus Rose, klausrose Consulting, Basel, Switzerland Costs: Industry CHF 600; Academia CHF 300; registration at firstname.lastname@example.org
09.30h Registration & Coffee
Masterclass Pediatric Drug Development
Rationale & description
Regarding children, drug development faces two realities: the real world and the regulatory view. Usually, these two views are compatible, but drug development in children is burdened by flawed concepts and institutional conflicts of interest so far barely acknowledged. At this interface of law, medicine and regulatory affairs, all players including clinicians, scientists and other industry professionals need a compass to navigate the jungle of confusing information and regulatory requirements that often contradict common sense.
FDA and EMA approve drugs for „children“ separately. The FDA defines „children“ as <17y, the EU as <18y, as if „children“ were another species. Both demand separate proof of efficacy in „children“: the FDA initial pediatric study plan (iPSP) 60 days after the end-of-phase-2 (EoP2) meeting; the EU a „pediatric investigation plan“ (PIP) years before marketing authoristation application (MAA). PIP negotiations take roughly one year. Without a PIP agreed by the EMA Pediatric Committee (PDCO) MAA is blocked.
Newborns are vulnerable and immature, but grow and mature fast. The FDA/EMA age limits are artificial, confering an inadequate, pseudo-physiological connotation to administrative age limits. The word „child“ has different meanings. With „children“ we associate small, vulnerable persons; but administratively, anybody <17/18y is a „child“. US and EU pediatric laws are semantically based on the blur between different meanings of the word „child“.
Regulatory „pediatric“ challenges include
1) Negotiating „pediatric“ development for new drugs with FDA and EMA. Companies should try to develop drugs without separate „pediatric“ efficacy studies that mostly medically lack sense or even harm patients. Adolescents should be included into pivotal adult studies, even if this requires additional paperwork. The FDA is often more pragmatic, but the US Research to Accelerate Cures and Equity (RACE) for Children Act will lead to FDA „pediatric“ demands in anticancer drugs from 2020 on.
2) Ongoing PIPs and clinical studies that cost millions per year and are medically questionable, but the EMA insists on their continuation. But the EMA will not dare to openly antagonize clinicians involved in such studies and ethics committees that can suspend them.
3) Strategic questions including collaboration with patient advocacy groups, challenging FDA/EMA demands with Institutional Review Boards/ ethics committees, in the media, in the courts, in the scientific press, and in the social media.
To deal with regulatory „pediatric“ challenges, you need solid knowledge in pharmacology, science, developmental physiology, history of pediatric laws & FDA/EMA decisions, the outcome of FDA/EMA-demanded studies, and diplomacy. The masterclass will help.
Industry CHF 600
Academia, patient advocacy groups CHF 300
Students can apply for reduced price at CHF 100
Registration at email@example.com